FDA approves first Tau imaging agent for Alzheimer Disease

The FDA has approved the use of intravenous imaging agent flortaucipir F18 (Tauvid; Avid Radiopharmaceuticals) to help image tau pathology in the brain for adult patients with cognitive impairment who are being evaluated for Alzheimer disease.

“Alzheimer disease is a devastating condition that affects millions of Americans. This approval will provide health care professionals with a new type of brain scan to use in patients being evaluated for Alzheimer disease,” said Charles Ganley, MD, director, Office of Specialty Medicine, Center for Drug Evaluation and Research, FDA, in a statement.

For the full article click HERE.